March 9, 2016 —Hebrew University students developed a lifesaving device following a wave of stabbing attacks that leaves some victims with collapsed lungs.
Pneumothorax is the collection of air in the pleural space (the tiny area between the two layers of the thin covering that protects and cushions the lungs) separating the lung from the chest wall, causing it to collapse and resulting in suffocation. Pneumothorax is caused by chest trauma, and is believed to be responsible for over a third of preventable deaths on the battlefield and in terror attacks.
The current treatment involves two steps: a fast needle decompression of the thorax (between the neck and abdomen, where the lungs and other vital organs are located), followed by a 10-minute tissue separation and tube insertion procedure into the chest to drain air and blood, allowing the lung to re-inflate.
“This is a very laborious and technically difficult procedure,” said Dr. Ariel Drori, an internal medicine expert at Hadassah Medical Center, “leading caregivers to neglect the second step in favor of rapid evacuation from the scene to the hospital.”
A recent wave of stabbing attacks in Israel that left dozens of people dead or wounded made the need for an alternative imperative. Members of the BioDesign: Medical Innovation program, created by The Hebrew University of Jerusalem and its affiliated Hadassah Medical Center, set out to solve this problem.
To address this challenge, Dr. Drori partnered with Yoav Kan-Tor and Bettina Nadorp, engineering students at The Hebrew University’s Alexander Grass Center for Bioengineering, along with Dr. Liran Levy, a pulmonologist from Hadassah Medical Center, and Chen Goldstein, an MBA student at The Hebrew University. Together they developed ThoraXS.
ThoraXS is a one-handed thoracic portal opener that shortens the procedure time of chest-tube insertion from minutes to less than 30 seconds. Its closed knife-shape allows fast penetration of the pleural space, and its mechanical opening mechanism enables rapid and easy opening of a portal through which a chest tube can be quickly inserted. ThoraXS is thus a single-step, rapid life-saving solution for treating pneumothorax.
Professor Yaakov Nahmias, director of Hebrew University’s Alexander Grass Center for Bioengineering, said: “Our students responded to terror attacks by developing lifesaving medical devices, an approach that is the very essence of our BioDesign: Medical Innovation program. ThoraXS is a lifesaving innovation that exemplifies our commitment to helping the local and global communities through practical research and development projects.”
Nahmias added that ThoraXS’s market potential was estimated at $300 million annually, and that continued investment is actively being sought.
The innovations produced by the Biodesign program participants are commercialized by Yissum, the technology transfer company of The Hebrew University of Jerusalem, and Hadasit, the technology transfer company of the Hadassah Medical Center.